Should Brandon Meyers recommend a delay in the launch? Justify your decision (by case facts and data) Brandon Meyer should recommend a delay in the launch. Although there are several downsides to a delay, the pros greatly outweigh the costs.

As mentioned in the case, Grist took 20 years and millions and dollars to come up with. The time and effort invested In the creation of the drug demands that the stage is set properly for its launch, to allow Ell Lilly to reap the maximum benefits room It.

We Will Write a Custom Case Study Specifically
For You For Only $13.90/page!

order now

While a timely launch would benefit Ell Lilly In the short run such as providing higher investor confidence, a slipshod launch could hurt Ell Levels profits In the long run, such as setting a sub-optimal pricing for Glass. In addition, Ell Lilly has no approved competition at the moment and are protected by patent. As such, a three to six month delay would not cause them to lose out In first mover advantage.

Question 2: What are advantages and disadvantages of a delay?

There are several advantages to a delay. Firstly, It would allow them to revise their pricing strategy. With the FDA limiting their market to adult patients with severe slumps, Ell Lilly should consider increasing the price of their drug to reap back their high cost of investments. Secondly, it can allow them to re-explore their distribution channels. A significant percentage of patients who died from sepsis did so within a week of interacting the disease.

As such, demands for the drug are likely to be urgent.

As such, they may consider using Synchs, which is an emergency-response delivery service. In addition, this can reduce the need for hospitals to stock up on the expensive drug. However, there are disadvantages as well. The pharmaceutical industry is extremely competitive. A delay may result in a loss of investor confidence which could cost Eli Lilly to lose out to competitors.